MDM2 and dedifferentiated liposarcoma: Additionally, Milademetan (RAIN‐32), an oral MDM2 inhibitor, has initiated clinical trials, including a randomized phase 3 trial (MANTRA [RAIN‐3201]; NCT04979442) in patients with unresectable or metastatic DDLPS.31